REFEREE REPORTS
Referee #1:
In this Ms Verhage, Toonen and colleagues unravel an important component of an ERK-dependent pathway of presynaptic short-term inhibition that can be driven by postsynaptically released endocannabinoids via presynaptic CB1 receptors or mGluR dependent pathways of homeostatic plasticity. Specfically, they convincingly demonstrate that activated ERK phosphorylates the essential presynaptic release factor Munc18-1 at multiple sites, most importantly S241A in vitro and in living animals in vivo as beautifully demonstrated by a fear conditioning paradigm. Munc18-1 phosphorylation by ERK1/2 is regulated by neuronal network activity as well as external cues, i.e. BDNF stimulation or CB1 receptor activation. Mechanistically, it is shown using viral rescue experiments in autaptic cultures from Munc18-1 knockout mice that expression of a non-ERK phosporylatable mutant version of Munc18-1 (S241A) increases both evoked as well as spontaneous presynaptic neurotransmitter release and elevated the size of the readily releasable pool (RRP). Conversely, hyperphosphorylation of Munc18-1 mimicked by expression of S241D mutant Munc18-1 is associated with reduced synapse number, reduced evoked and spontaneous neurotransmission, and elevated SV numbers resulting from a reduced release probability. This impaired basal neurotransmission caused by Munc18-1 S241D originates from facilitated degaradtion of the mutant Munc18-1 protein by the ubiquitin-proteasome pathway. Finally, the authors demonstrate that ERK-mediated phsophorylation of Munc18-1 prevents endocannabinoidand mGluR induced presynaptic depression in hippocampal autaptic neurons in culture. Overall, this beautiful new study convincingly demonstrates a novel role for ERK-mediated phosphorylation of Munc18-1 as a key mechanism underlying presynaptic short-term inhibition in vitro and in vivo. These findings are of high interest to the neuroscience community as well as to cell biologists interested in neurotransmisson.
I have only a few minor suggestions for improvement of the Ms. 1. In Fig. 5H it appears that S241A is expressed at elevated levels compared to the WT protein, while both proteins seem to be present at similar levels when assayed by immunofluorescence in panels B and C. The authors may want to resolve this discrepancy.
2. The discussion seems a bit superficial. I suggest to discuss in a some more detail how the new results fit with previously described mechanisms of presynaptic inhibition via CB1, e.g. the pssible involvement of calcium channels at inhibitory synapses.
3. The resolution of panel C in Fig. 4 seems low and would need improvement to reach publication quality.
Referee #2:
Schmitz et al report that presynaptic inhibition mediated by cannabinoid and metabotropic receptors (CB1R and mGluR2/3) require ERK-dependent phosphorylation of Munc18-1. The two main conclusions are: a) Munc18-1 is a presynaptic ERK substrate; b) ERK-dependent Munc18-1 phosphorylation reduces synaptic transmission and could be involved in endocannabinoid and mGluR2/3-mediated suppression of glutamate release. If true, the findings seem to challenge current views on the mechanism by which these receptors transiently suppress transmitter release. The study presents a number of experimental approaches that do not necessarily talk to each other. While most of the experiments are well designed, a number of the authors' claims are not fully supported by the data. Moreover, the study heavily relies on the overexpression of two Munc18-1 mutants in autaptic neurons. Given the potential impact of the authors' claims, the main conclusions of this study should be validated using alternative approaches and by testing a few predictions.
MAJOR CONCERNS
1. Several studies have demonstrated that a reduction in presynaptic calcium influx is responsible for the fast, transient suppression of transmitter release upon activation of CB1Rs or mGluRs. In contrast, the authors suggest that ERK-dependent phosphorylation of Munc18-1 is a major mechanism in this transient suppression. It is possible that the authors' findings could be due to the rather non-physiological approach used in this study -e.g. overexpression of mutant forms of Munc18-1 in autaptic neurons. If both reduction in calcium influx and Munc18-1 phosphorylation coexisted, the authors should determine their relative contribution under more physiological conditions. At least they should test whether PD98059 and some other ERK-pathway inhibitor blocks WIN-mediated suppression of transmission and Depolarization-induced Suppression of Excitation (DSE) in both autaptic neurons and acute brain slices.
2. The authors claim that Munc18-1 gets phosphorylated by activation of presynaptic receptors that are implicated in negative feedback signaling. However, the mechanism by which BDNF and LY379268 promote Munc18-1 phosphorylation could be indirect and not necessarily presynaptic. Moreover, they also claim that ERK-dependent Munc18-1 phosphorylation plays a key role in multiple retrograde signaling pathways. However, not a single manipulation directly tests this possibility, and only pharmacological tools were used. As indicated above, they should examine the role of phosphorylated Munc18-1 on endocannabinoid signaling (e.g. by testing DSE). As for mGluR2/3 activation, it is important to know whether LY379268 reduces transmitter release in naïve autapses (PPF, failure rate, mEPSC).
3. It appears that ERK increases transmitter release by phosphorylating synapsin but decreases transmitter release by phosphorylating Munc18-1. How does it work? What is the functional consequence of phosphorylated Munc-18 and phosphorylated syntaxin on neuron output? Do these actions occur in the same synapses? The authors claim different time domains but the evidence in support of this possibility does not seem to be that strong. This issue should be thoroughly discussed.
4. Does the WIN-induced suppression wash out? Show recovery post washout.
5. Consistent with a reduction in both evoked EPSC amplitude and mEPSC frequency, PPR was increased by expressing the S241D mutant in autaptic neurons. In contrast, PPR was unchanged by the S241A mutant, which clearly increased evoked transmission, mEPSC activity and RRP size. Do the authors have an explanation for this dissociated phenotype? OTHER POINTS Abstract, first sentence: presynaptic CB1Rs regulate synaptic strength not only by *transiently" inhibiting secretion. CB1Rs also mediate long-term suppression of neurotransmitter release (even in autaptic neurons; see Kellog et al, J. Neurophysiol, 2009). Also, while the effects of both CB1R and mGluR2/3 were analyzed in this study, only CB1Rs are mentioned in the abstract.
We thank the reviewer for his/her positive evaluation of our manuscript ("beautiful new study"). This reviewer concludes that the manuscript will be "of high interest to the neuroscience community as well as to cell biologists". This reviewer raises 3 minor issues:
1: In Fig. 5H it appears that S241A is expressed at elevated levels compared to the WT protein, while both proteins seem to be present at similar levels when assayed by immunofluorescence in panels B and C. The authors may want to resolve this discrepancy. Reply: The reviewer is correct. In Figure 5H we perform measurements of WT and S241A levels in cultures with 3-times more cells/well than in Figure 5B -C, which increases spontaneous activity and activates ERK. In these cultures S241A levels are increased compared to WT, as predicted. These high-density cultures were also used for analysis in Figure 5E (yielding similar results). We have added a better description to the result section at page 13 lines 5-7
2:
The discussion seems a bit superficial. I suggest to discuss in a some more detail how the new results fit with previously described mechanisms of presynaptic inhibition via CB1, e.g. the possible involvement of calcium channels at inhibitory synapses. Reply: we agree with the reviewer and we have now thoroughly revised the discussion section to discuss our findings in the light of previously described mechanisms (including involvement of calcium channels).
3: The resolution of panel C in Fig. 4 seems low and would need improvement to reach publication quality.
Reply: this was likely caused by the pdf conversion in the original submission, panel 4C in the final figure is now of high resolution.
Reply to Referee #2:
We thank the reviewer for his/her thorough and balanced review of our manuscript. The reviewer argues that given the potential impact of our findings, validation via alternative approaches is required. This reviewer raises 5 major issues:
Several studies have demonstrated that a reduction in presynaptic calcium influx is responsible for the fast, transient suppression of transmitter release upon activation of CB1Rs or mGluRs. In contrast, the authors suggest that ERK-dependent phosphorylation of Munc18-1 is a major mechanism in this transient suppression. It is possible that the authors' findings could be due to the rather non-physiological approach used in this study -e.g. overexpression of mutant forms of Munc18-1 in autaptic neurons. If both reduction in calcium influx and Munc18-1 phosphorylation coexisted, the authors should determine their relative contribution under more physiological conditions. At least they should test whether PD98059 and some other ERK-pathway inhibitor blocks WIN-mediated suppression of transmission and Depolarization-induced Suppression of Excitation (DSE) in both autaptic neurons and acute brain slices.
Reply: We agree with the reviewer that some of the conditions used in our experiments are "rather non-physiological". This is of course common practice in many published experiments on the mechanisms of synaptic plasticity. As requested, we tested the effect of ERK inhibitors on DSE in hippocampal slices (new Figure Figure  S7D-F) . We wish to point out that these conditions, ERK-pathway inhibition and DSE induction, are also "rather non-physiological". In hippocampal slices, WIN-mediated depression and DSE were reduced by >60% by ERK-pathway inhibition. This confirms that the ERK/Munc18 pathway is indeed a major pathway in CB1R-mediated depression of synaptic transmission. It also leaves room for other pathways like reduction of presynaptic calcium influx to contribute to CB1R-mediated depression. We address this now more explicitly in the Discussion section, also the fact that our data do not challenge the CB1-dependent calcium channel inhibition. The new mechanism most likely co-exists with channel inhibition. In autaptic neurons, we found it was impossible to obtain good inhibition of the ERKpathway using PD98059 and U0126. These blockers did not reduce phospho-ERK levels in all neurons, as we found out in control experiments, directly assessing ERK-induced phosphorylation of its substrates (New Figure S7G , H) Although inhibition was incomplete, it significantly reduced the amplitude and duration of DSE and blocked WIN-mediated suppression in a subset of neurons (20%) but not in all. Our previous data provided some clues on the reasons why inhibition was incomplete in autaptic neurons. ERK itself appears to remain in a phosphorylated state much longer than in hippocampal slices (Fig, 3C) . We have added a short discussion on this possibility to the legend of Fig S7, Reply: We agree with the reviewer that BDNF and LY379268-induced phosphorylation of Munc18-1 may be indirect and not presynaptic. These compounds were used to show that several pathways that lead to ERK activation result in phosphorylation of Munc18-1. Two of these compounds, LY379268 and WIN, which activate presynaptic receptors and lead to ERK activation resulted in a reduction of synaptic transmission that depended on Munc18 phosphorylation. We have now assessed the contribution of this ERK-pathway in DSE and WIN-mediated suppression of release in slices and autapses to show that this pathway significantly contributes to CB1R-mediated suppression of release. See also our answer to Q1 above. The group of Richard Miller has studied the effect of mGluR2/3 activation in autaptic cultures (Bushell et al., 1999). They find a similar reduction of EPSC amplitude and mEPSC frequency in wild type autapses upon mGluR2/3 activation as we find in munc18-1 null mutant autapses rescued with M18 WT . Hence, the effect of both WIN and LY379268 application on synaptic transmission is similar in WT autapses and munc18-1 null mutant autapses rescued with M18 WT . We added this to the result section on page 16. Reply: We agree that this issue deserves more discussion. We have now devoted a paragraph in the Discussion to this topic (p 19). We have emphasized that our data confirm ERK-dependent synapsin phosphorylation, (and now show that it occurs during fear conditioning); that phosphorylation of synapsin and Munc18-1 probably occurs in the same synapses, but that the evidence for the relevance of ERK-dependent synapsin phosphorylation is based on PD98059 application (Jovanovic et al 2000), i.e. manipulations that block positive as well as negative actions of ERK-substrates. To our knowledge, the critical experiment, to express a phosphorylation-deficient synapsin mutant on a (triple) null background, like we present for Munc18-1, has not been performed. In fact, EPSC amplitudes are not affected in the synapsin triple knock-out, (Gitler et al., 2004 ). We agree with the reviewer that the evidence in support of different time domains is not strong. We have removed this idea in the revised Discussion.
It appears that ERK increases transmitter release by phosphorylating synapsin but decreases

Does the WIN-induced suppression wash out? Show recovery post washout.
Reply: In figure 7 we apply WIN for only 30 sec and observe a strong suppression in EPSC amplitude that lasts at least 4 minutes ( Figure 6B and E). WIN-induced suppression is reversible in both autaptic neurons and in slices but recovery is relatively slow requiring on average 30 minutes after WIN application. We added a supplemental figure showing WIN washout in slices and autapses (new figure S6) . 
Consistent with a reduction in both evoked EPSC amplitude and mEPSC frequency, PPR was increased by expressing the S241D mutant in autaptic neurons. In contrast, PPR was unchanged by
OTHER POINTS
Abstract, first sentence: presynaptic CB1Rs regulate synaptic strength not only by *transiently" inhibiting secretion. CB1Rs also mediate long-term suppression of neurotransmitter release (even in autaptic neurons; see Kellog et al, J. Neurophysiol, 2009). Also, while the effects of both CB1R and mGluR2/3 were analyzed in this study, only CB1Rs are mentioned in the abstract.
Reply: we fully agree with the reviewer and changed the abstract and removed "transiently" and added a statement on mGluR2/3. We thank the reviewer for pointing this out.
Page 8, ERK auto-phosphorylation,provide some quantification.
Reply: we added quantification of the ERK auto-phosphorylation to figure 2F.
Page 11, Synaptic Munc-18 levels, describe how synaptic v. somatic Munc-18 was quantified. Not listed in the text or Methods.
Reply: we are sorry for this omission and added description to the methods section at p27.
Page 14, line 2, "...to produce presynaptic inhibition (Derkinderen et al, 2003; Kellogg et al, 2009)". Wrong citations, revise.
Reply: we thank the reviewer for pointing this out and changed the citations.
Page 14, lines 4-6: indicate in the text what preparation (cells/tissue) was used in these experiments.
Reply: we have added this to the main text at p14.
Page 17, lines 5-7: provide some references. Reply: we added references for these statements.
The discussion is extremely short and should be expanded. Reply: we agree with the reviewer and we have now thoroughly revised the discussion to discuss our findings in light of previously described mechanisms.
The title is too open ended (CB1R or mGluR2/3 should be mentioned).
Reply: we agree and changed the title to: "Presynaptic inhibition upon CB1 and mGlur2/3 receptor activation requires ERK/MAPK phosphorylation of Munc18-1" Fused 2 = RRP 2 P vr 2
Gitler D, Takagishi Thank you for submitting your revised manuscript to The EMBO Journal. Your study has now been re-reviewed by referee 2 and the comments are provided below. As you can see, the referee appreciates the introduced changes and supports publication here. There are just a few minor issues to sort out before formal acceptance here.
REFEREE REPORT
Referee #2:
The authors have properly addressed most of my concerns by adding new results and significantly expanding Discussion. I only have a few minor comments that the authors may want to address.
-In page 16, the authors conclude: "Hence, multiple retrograde signaling pathways activate ERKdependent Munc18 phosphorylation, which reduces synaptic output." What are the "multiple retrograde signaling pathways" the authors refer to? This conclusion is rather misleading since their study analyzes only one retrograde signaling pathway.
-The authors indicate that PD98059 and U0126 have no effect on glutamatergic autaptic transmission (Fig. S7A , note that figure legend and figure panel do not match). They should provide some information about EPSC time course. In addition, they should test whether EPI affect evoked synaptic transmission in acute slices by monitoring fEPSPs (e.g 20-30 min baseline, and at least one hour EPI bath application). Reply: the "multiple retrograde signaling pathways" referred to the multiple receptor pathways. We agree that our phrasing might be unclear and changed the sentence on p16 to "activation of multiple receptor systems leads to ERK-dependent Munc18 phosphorylation, which reduces synaptic output". Reply: To show that PD98059 and U0126 have no effect on glutamatergic autaptic transmission we have added example EPSC traces prior to and after EPI treatment to Figure EV5C and average EPSC rise and decay times prior to WIN55,212-2 application to Figure EV5F . In addition, we have added average EPSC amplitudes from control and EPI-treated neurons during baseline recordings prior to DSE and WIN application in acute slices as new Figure 7A and 7E, as requested by the reviewer. Together, these additional experiments show that PD98059 and U0126 have no effect on glutamatergic transmission in autapses and hippocampal slices. Is there an estimate of variation within each group of data?
Is the variance similar between the groups that are being statistically compared?
Yes
Yes, data samples were tested for normal distribution with the Kolmogorov and Smirnov test Yes, groups were tested for heterogeneity of variance with the method of Bartlett. For multiple group comparisons, one--way ANOVA was used if allowed otherwise the non--parametric Kruskal--Wallis test was used.
Not always, in case of unequal variance Welch correction was used or KW test for >2 groups.
YOU MUST COMPLETE ALL CELLS WITH A PINK BACKGROUND 
For figure 2, based on publised data we expected a large effect size upon footshock (0.7--0.8) based on this assumption the group size (5 mice/group) resulted in a calculated a prior power of 0.8 Sample size were chosen to ensure adequate power with the expected effect sizes (see above). P33
No samples were excluded from analysis
The experimentator was blind to genotype and/or compound in all experiments in the manuscript.
Mice were dived randomly in 3 groups by animal caretakers that did not excecute the experiment. P30
The experimentator was blind to genotype and/or compound in all experiments in the manuscript.P33
The experimentator was blind to genotype. After foot shock experiment hippocampi were extracted, anonymized and transferred other experimentator for protein analysis. P33Anonymization code was broken after full analysis of protein expression profiles (Figure 2 figure panels include only data points, measurements or observations that can be compared to each other in a scientifically meaningful way. graphs include clearly labeled error bars for independent experiments and sample sizes. Unless justified, error bars should not be shown for technical replicates. if n< 5, the individual data points from each experiment should be plotted and any statistical test employed should be justified Please fill out these boxes  (Do not worry if you cannot see all your text once you press return) a specification of the experimental system investigated (eg cell line, species name).
Each figure caption should contain the following information, for each panel where they are relevant:
Captions
The data shown in figures should satisfy the following conditions:
Source Data should be included to report the data underlying graphs. Please follow the guidelines set out in the author ship guidelines on Data Presentation. a statement of how many times the experiment shown was independently replicated in the laboratory.
Any descriptions too long for the figure legend should be included in the methods section and/or with the source data.
Please ensure that the answers to the following questions are reported in the manuscript itself. We encourage you to include a specific subsection in the methods section for statistics, reagents, animal models and human subjects.
In the pink boxes below, provide the page number(s) of the manuscript draft or figure legend(s) where the information can be located. Every question should be answered. If the question is not relevant to your research, please write NA (non applicable).
B--Statistics and general methods
the assay(s) and method(s) used to carry out the reported observations and measurements an explicit mention of the biological and chemical entity(ies) that are being measured. an explicit mention of the biological and chemical entity(ies) that are altered/varied/perturbed in a controlled manner.
the exact sample size (n) for each experimental group/condition, given as a number, not a range; a description of the sample collection allowing the reader to understand whether the samples represent technical or biological replicates (including how many animals, litters, cultures, etc.). This checklist is used to ensure good reporting standards and to improve the reproducibility of published results. These guidelines are consistent with the Principles and Guidelines for Reporting Preclinical Research issued by the NIH in 2014. Please follow the journal's authorship guidelines in preparing your manuscript.
PLEASE NOTE THAT THIS CHECKLIST WILL BE PUBLISHED ALONGSIDE YOUR PAPER
